Method for administrating preparations containing peramivir and/or derivatives thereof

Abstract

The invention relates to a method for administrating preparations containing peramivir and / or derivatives thereof. Administration is carried out through inhalation. The method can be used for treating cold caused by influenza viruses. By adopting the administration method provided by the invention, not only can dependence on the single variety of drugs such as oseltamivir and zanamivir be reduced and new drug resistant virus strains generated by using the single variety in quantity be avoided but also the method which is favorable for greatly improving the bioavailability compared with oral administration or intravenous drip is provided for peramivir and / or derivatives thereof; more importantly, the method which has the advantages of small drug dose, less side effects and high effect taking speed is provided.

Description

technical field [0001] The invention belongs to the field of pharmaceutical preparations, in particular to (1S, 2S, 3S, 4R)-3-[(1S)-1-acetylamino-2-ethyl-butyl]-4-guanidino-2-hydroxyl-cyclo Pentyl-1-carboxylic acid (C 15 h 28 N 4 o 4 : peramivir) and derivatives thereof such as pharmaceutically acceptable salts, esters, hydrates or amorphous compounds as neuraminidase inhibitors, through direct respiratory administration of lung targets for the treatment of influenza. Background technique [0002] As we all know, influenza (Influenza) is an acute respiratory infectious disease caused by influenza virus. It is highly contagious and has a high incidence rate, which can easily cause outbreaks or pandemics. [0003] According to the World Health Organization (WHO), the outbreak of H7N9 bird flu in 2013 had infected 132 people as of May 30, of which 37 died, with a mortality rate as high as 28%. The H1N1 swine flu (Swine Flu) epidemic from 2009 to 2010 has laboratory-confirm...

AI Technical Summary

Problems solved by technology

A 2011 study reported that new strains of swine flu emerging in Asia had developed some resistance to Roche's Tamiflu and GSK's Reganza without significantly reducing susceptibility to peramivir

However, due to great difficulties, the oral dosage form of peramivir has been discontinued, and even the more convenient intramuscular injection dosage form cannot be made. Currently, only intravenous drip is being used for clinical research